Podcast Q&A: Cell & Gene Therapies
In this episode of tHEORetically Speaking, join Dr. Pamela Landsman-Blumberg, Amanda O’Hora, and Ajay Keshava from Magnolia Market Access, who answer questions from a recent webinar on how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful approvals and market adoption.
For more information, to watch the webinar, or access other resources, click here.
Associated Webinar: Cell & Gene Therapies – Beginning with the End in Mind
Similar Podcasts
Podcast Q&A: The Benefits of Linking SDOH with Other Real-World Data
This podcast segment features the Q&A from Magnolia Market Access’ April 6, 2023 webinar with HealthEconomics.Com.
Additional Content From Magnolia Market Access
Cell & Gene Therapies – Beginning with the End in Mind
This webinar discusses how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful approvals and market adoption.
Finding Value in Linking Real-World Data with Social Determinants of Health
Hear Pamela Landsman-Blumberg and Rick Chapman highlight the importance of SDOH and discuss examples of how claims data and EMR linked with SDOH can inform use cases.